Furthermore, they are monitored regularly with respect to targeted patient outcomes, including dialysis adequacy (to ensure sufficient removal of waste from blood); bone and mineral disorder (e.g., to prevent high calcium in the blood or hypercalcemia); phosphorous level; regulation of blood pressure; and hemoglobin (Hb) to manage anemia among other conditions. This evidence concerns the gene GSTM1 and Hypercalcemia.